Table III.
Joint-effect analysis of prognosis-related genes for overall survival in the GSE14520 cohort.
| Group | Expression
|
Overall survival
|
|||||
|---|---|---|---|---|---|---|---|
| JAK2 | STAT5A | STAT6 | Events/total | MST (months) | Adjusted HR (95% CI) | Adjusted P-valuea | |
| 1 | Low | Low | 34/61 | 32.6 | Ref. | 0.002b | |
| 2 | Low | High | 33/90 | NA | 0.572 (0.340-0.961) | 0.035b | |
| High | Low | ||||||
| 3 | High | High | 15/61 | NA | 0.339 (0.181-0.638) | 0.001b | |
| I | Low | Low | 31/56 | 32.6 | Ref. | <0.001b | |
| II | Low | High | 37/100 | NA | 0.443 (0.269-0.728) | 0.001b | |
| High | Low | ||||||
| III | High | High | 14/56 | NA | 0.326 (0.171-0.619) | 0.001b | |
| A | Low | Low | 33/61 | 33.0 | Ref. | 0.001b | |
| B | Low | High | 36/90 | NA | 0.569 (0.350-0.927) | 0.023b | |
| High | Low | ||||||
| C | High | High | 13/61 | NA | 0.287 (0.149-0.544) | <0.001b | |
| i | Low | Low | Low | 21/34 | 28.2 | Ref. | <0.0001b |
| ii | Low | Low | High | 35/76 | NA | 0.485 (0.277-0.851) | 0.012b |
| Low | High | Low | |||||
| High | Low | Low | |||||
| iii | Low | High | High | 18/64 | NA | 0.263 (0.135-0.513) | <0.0001b |
| High | Low | High | |||||
| High | High | Low | |||||
| iiii | High | High | High | 8/38 | NA | 0.208 (0.090-0.478) | <0.001b |
a
P-values were adjusted for tumor size, cirrhosis, α-fetoprotein and Barcelona Clinic Liver Cancer stage;
b
significant P-values and 95% CI. JAK2, Janus kinase 2; STAT, signal transducer and activator of transcription; NA, not available; MST, median survival time; HR, hazard ratio; 95% CI, 95% confidence interval; Ref., reference.